IGC Pharma is a clinical-stage pharmaceutical company with a strong focus on improving the health and well-being of women and their families. They specialize in the discovery and development of innovative therapies for various conditions, including Alzheimer's disease, premenstrual syndrome (PMS), dysmenorrhea, and sleep disorders. Formerly known as India Globalization Capital, Inc., IGC Pharma is committed to scientific excellence, patient-centeredness, and collaboration.

They strive to advance the understanding and treatment of these conditions while addressing the unique health needs and concerns of women across the lifespan. Currently, their revenue mainly comes from women's wellness products, but their future focus is on investigational drugs for Alzheimer's disease. In fiscal 2022, they entered Phase 2 with IGC-AD1, an investigational drug that has shown efficacy in reducing neuropsychiatric symptoms in dementia due to Alzheimer's.

They have also acquired and started working on a molecule called TGR-63, which shows promise in reducing neurotoxicity in Alzheimer's cell lines. For PMS and dysmenorrhea, IGC Pharma aims to develop effective therapies that can alleviate symptoms and improve the quality of life for those affected. While there is no known cure for these conditions, their goal is to provide innovative solutions that help manage symptoms and promote overall health and well-being.

Through their dedication to innovation and bringing novel therapies to the market, IGC Pharma strives to improve the lives of millions of individuals affected by these conditions